4-Methyl-2-(2-nitro-vinyl)-thiophene | 1204576-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 4-Methyl-2-(2-nitro-vinyl)-thiophene
• 英文别名: 4-Methyl-2-(2-nitroethenyl)thiophene；4-methyl-2-[(E)-2-nitroethenyl]thiophene
• CAS: 1204576-75-9
• 化学式: C₇H₇NO₂S
• 分子量: 169.204
• InChiKey: RKNCCLXHPUFHNE-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  74.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-甲基噻吩-2-甲醛 、 硝基甲烷 在 silica supported ethanolamine 作用下， 反应 24.0h， 生成 4-Methyl-2-(2-nitro-vinyl)-thiophene
  参考文献：
  名称：

  Synthesis of (E)-nitroalkenes Catalysed by Ethanolamine Supported on Silica

  摘要：

  A simple method for preparing (E)-nitroalkenes based on a Henry reaction in the presence of a heterogenized homogeneous catalyst consisting of silica-supported ethanolamine is proposed. With 4-substituted benzaldehydes, the reaction gives the corresponding (E)-nitrostyrenes in high yields and a short time. Heterocyclic carboxaldehydes also give good results, but the presence of an N or S atom in the ring has a slightly adverse effect on the reaction. The synthetic process is quite novel and interesting. The catalyst remains active and exhibits no substantial loss of activity or selectivity over up to three reaction cycles.

  DOI：

  10.1007/s10562-009-0223-5

文献信息

• [EN] ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS<br/>[FR] INHIBITEURS D'EZH2 (ENHANCER OF ZESTE HOMOLOG 2)
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2016066697A1

  公开（公告）日：2016-05-06

  This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homo log 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

  这项发明涉及到按照式（I）的新化合物，这些化合物是Enhancer of Zeste Homo log 2 (EZH2)的抑制剂，包括含有它们的药物组合物，它们的制备方法，以及它们在治疗癌症中的应用。
• [EN] ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS<br/>[FR] AMPLIFICATEUR DES INHIBITEURS DE L'HOMOLOGUE 2 DE ZESTE
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD

  公开号：WO2017002064A1

  公开（公告）日：2017-01-05

  This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

  这项发明涉及到按照式（I）的新化合物，这些化合物是增强子Zeste同源物2（EZH2）的抑制剂，以及含有它们的药物组合物，它们的制备过程，以及它们在治疗癌症方面的用途。
• Pyrazolopyrimidines, a process for their preparation and their use as medicine
  申请人：Danysz Wojciech

  公开号：US20080039476A1

  公开（公告）日：2008-02-14

  The invention relates to pyrazolopyrimidine derivatives of formula (I) wherein Y 1 , Y 2 and Y 3 independently are e.g. CR 10 , NH, S or O, whereby at least one of Y 1 , Y 2 and Y 3 represents CR 10 ; R 1 represents chloro or bromo; R 2 , R 3 , R 4 , R 5 , R 6 and R 7 represent e.g. hydrogen or C 1 -C 6 -alkyl, and R 10 represents e.g. hydrogen, halogen or phenyl; which are potent mGluR5 modulators and are e.g. useful for the treatment of various neurological disorders.

  本发明涉及式(I)的吡唑并嘧啶衍生物，其中Y1、Y2和Y3独立地是例如CR10、NH、S或O，其中至少一个Y1、Y2和Y3代表CR10；R1代表氯或溴；R2、R3、R4、R5、R6和R7代表例如氢或C1-C6烷基，而R10代表例如氢、卤素或苯基。这些化合物是有效的mGluR5调节剂，例如用于治疗各种神经系统疾病。
• 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP2090576A1

  公开（公告）日：2009-08-19

  The invention relates to 6-halo-pyrazolo[1,5-a]pyridines of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders. wherein A represents -NR3R4 with R3 and R4 as described herein.

  本发明涉及式（I）的6-卤代吡唑并[1,5-a]吡啶以及其药学上可接受的盐。本发明还涉及制备这些化合物的方法。本发明的化合物是mGluR5调节剂，因此对于控制和预防急性和/或慢性神经系统疾病有用。 其中，A表示-NR3R4，其中R3和R4如本文所述。
• PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE
  申请人：Merz Pharma GmbH & Co. KGaA

  公开号：EP2054421A1

  公开（公告）日：2009-05-06